Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFATRIM PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus SULFATRIM PEDIATRIC.
SODIUM SULFACETAMIDE vs SULFATRIM PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking the synthesis of folic acid and ultimately nucleic acid synthesis, leading to bacteriostatic activity.
Sulfamethoxazole inhibits dihydropteroate synthase, blocking bacterial folic acid synthesis; trimethoprim inhibits dihydrofolate reductase, blocking reduction of dihydrofolate to tetrahydrofolate. Sequential blockade leads to bactericidal activity.
1-2 drops of 10% or 30% solution into conjunctival sac every 2-3 hours during waking hours for 7-10 days.
Sulfatrim Pediatric suspension contains sulfamethoxazole 200 mg and trimethoprim 40 mg per 5 mL. For patients >40 kg, dose is 800 mg SMX/160 mg TMP orally every 12 hours for 10-14 days.
None Documented
None Documented
7-12 hours in normal renal function; prolonged to 20-50 hours in renal impairment.
Sulfamethoxazole: 9-11 hours; Trimethoprim: 8-10 hours; prolonged in renal impairment (e.g., CrCl <30 mL/min).
Renal: 85-100% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Renal: 50-70% of total sulfamethoxazole (SMX) and 30-50% of total trimethoprim (TMP) are excreted unchanged in urine; the remainder as metabolites; biliary/fecal excretion is minimal.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic